Scott & White's Cancer Research Institute (CRI) is participating in an international study that targets adult relapsed or refractory B-cell Non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
"This study is important in our efforts to find new and better ways to treat patients with leukemia or lymphoma," said Arthur E. Frankel, M.D., director of Scott & White's Cancer Research Institute, and principal investigator for the Temple portion of the study. "Scott & White, as well as the entire Central Texas community, are fortunate to be included in this international research."
The Phase I/II study is open to eligible patients with previously treated B-cell non-Hodgkin's lymphoma (NHL), B-cell chronic lymphocytic leukemia (CLL), to include small lymphocytic lymphoma (SLL). B-cell lymphomas account for 80-90% of all Non-Hodgkin's Lymphomas. The clinical trial will evaluate the safety, tolerability, and efficacy of an investigative therapeutic research agent called CAT-8015.
This research will ultimately include 30 sites in the U.S., Canada and Europe and from 110 to 140 subjects. The study will last about 30 months.
"We want to determine if this agent is effective in destroying cancer cells using varying doses," said Dr. Frankel.
|Contact: Katherine Voss|
Scott & White Healthcare